Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
about
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response.Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patientsFibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs.Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2.IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma.Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation.
P2860
Q33842239-683F3CD6-BD41-4673-AF10-E93CA82BDBADQ34007851-1CD68570-E588-4D30-93E1-657EB03446EBQ34191840-2C6E09DE-875C-4D46-AF5D-D517A6427C34Q36541206-810B4E08-7F62-4A06-92BD-9079F837065EQ37619741-B577E34A-2C19-466A-9256-39CC30933935Q38002889-86BF0D69-1301-445D-89D5-88706579ADC8Q39075044-8C6CF2B6-5D3F-4C18-B8DA-37616DAD81F1Q41504212-E16DD14E-DC88-4AC2-BEEE-36EA6EAA980CQ42276236-0403B65D-4CCD-4733-B1D7-3D8DF609DECAQ42995295-6DE5D785-A78E-4F6D-A0F8-3355752FE2F2Q43031605-E3650F49-5F56-4618-ADBE-0721DDC737F7Q43037030-33EEC492-7C1C-47C2-A623-8B73965466E8Q43040465-72276CEC-4986-4100-BFD9-316807B8F4BCQ50551492-6F77B8F6-E80C-4E2A-8523-BB1570CEB8BE
P2860
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
@ast
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
@en
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
@nl
type
label
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
@ast
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
@en
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
@nl
prefLabel
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
@ast
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
@en
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
@nl
P2093
P2860
P50
P1476
Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.
@en
P2093
Barbro Gerdén
Björn Fischler
Filip Josephson
Olle Karlström
Per Sangfelt
Robert Schvarz
Rune Wejstål
Styrbjörn Friman
Swedish Consensus Group
P2860
P304
P356
10.1080/00365540902998271
P577
2009-01-01T00:00:00Z